Phase II study of OPAXIO to be revealed

NewsGuard 100/100 Score
Editorial Checklist Reviewed
Sep 24 2009

Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that data from a Phase II study from Brown University of OPAXIO(TM) (paclitaxel poliglumex) combined with standard cisplatin and concurrent radiation in patients with advanced esophageal cancer will be presented by Dr. Howard Safran in an oral Proffered Papers session at the Annual Meeting of the International Society of Gastrointestinal Oncology in Philadelphia, Pennsylvania on Thursday, October 1st at 2:35 p.m. (Eastern time).

Source:

http://www.celltherapeutics.com

Posted in: Drug Trial News | Medical Condition News

Tags: , , , , , , , ,

Comments (0)

Suggested Reading

Mitochondrial fusion critical for adult neurogenesis and brain circuit refinement
New lab assay could make diagnosis and treatment of lung cancer easier
Novel therapeutic approach identified for overcoming resistance in B-cell leukemia
Stem cell therapy safe and potentially beneficial for spinal cord injury patients
New ovarian atlas paves the way for extended fertility and hormone restoration
Fluent BioSciences awarded NIH SBIR grant to commercialize low-cost million-cell transcriptome profiling kits
Discovery of new vascular cell type may pave way for novel strategies to treat cardiovascular diseases
Triple-negative breast cancer patients with high immune cell levels have lower relapse risk after surgery

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Study highlights how age affects nasal cell response to SARS-CoV-2